JUNIUS J. GONZALES, B.A.; MINDY S. BOHRER, B.A.; JONATHAN T. EDELSON, B.A.; A. MARK FENDRICK, B.A.; MARY F. MORRISON, B.S.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Katz and colleagues (1) have compiled an important and extensive review of proteinuria in patients with rheumatoid arthritis who are receiving oral gold treatments. We want to comment on two problems with this retrospective study and its conclusions.
First, an analysis of potentially confounding disease variables in the study groups is needed to assess the actual contribution of gold treatment to proteinuria independent of other factors. The authors themselves cite the increased risk of proteinuria in patients with other nonrheumatologic disorders (such as diabetes mellitus, urinary tract infections, or congestive heart failure). Also, because at least two
GONZALES JJ, BOHRER MS, EDELSON JT, et al. Proteinuria and Oral Gold Treatment. Ann Intern Med. 1985;102:561–562. doi: https://doi.org/10.7326/0003-4819-102-4-561
Download citation file:
Published: Ann Intern Med. 1985;102(4):561-562.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use